Theoretical thinking on guiding research and development of new drugs of traditional Chinese medicine.
10.19540/j.cnki.cjcmm.20210213.501
- Author:
Zhong-Qi YANG
1
;
Hui-Min TANG
1
;
Ya-Qin TANG
1
;
Yan-Ping DU
1
;
Wei-An YUAN
2
;
Bo LI
3
;
Chong ZOU
4
;
Jian-Yuan TANG
5
;
Rui GAO
6
;
Si-Yuan HU
7
;
Lei ZHANG
8
Author Information
1. the First Affiliated Hospital of Guangzhou University of Chinese Medicine Guangzhou 510407, China.
2. Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine Shanghai 201203, China.
3. Beijing Hospital of Traditional Chinese Medicine, Capital Medical University Beijing 100010, China.
4. Jiangsu Province Hospital of Chinese Medicine Nanjing 210029, China.
5. Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075, China.
6. Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing 100091, China.
7. First Teachig Hospital of Tianjin University of Traditional Chinese Medicine Tianjin 300192, China.
8. Shanghai University of Traditional Chinese Medicine Shanghai 201203, China.
- Publication Type:Journal Article
- Keywords:
clinical values of traditional Chinese medicine;
core pathogenesis;
new drugs of traditional Chinese medicine
- MeSH:
Drugs, Chinese Herbal/therapeutic use*;
Humans;
Medicine, Chinese Traditional;
Quality of Life;
Research;
Syndrome
- From:
China Journal of Chinese Materia Medica
2021;46(7):1686-1690
- CountryChina
- Language:Chinese
-
Abstract:
This article proposes that the research and development of new Chinese medicines should be based on the clinical values of traditional Chinese medicine(TCM), and expounds the multiple clinical values of new Chinese medicines such as therapeutic effects, adjuvant treatment effects, improvement of disease symptoms, improvement of quality of life, prevention of diseases, etc., so as to broaden the clinical indications of new Chinese medicines. It is pointed out that the clinical value of TCM determines the clinical efficacy evaluation method of new Chinese medicines, so as to construct a clinical evaluation system of new Chinese medicines with the characteristics of TCM. It is proposed that the clinical value of new Chinese medicines should be found under the guidance of TCM theo-ry and clinical practice, and the theoretical innovation of TCM should be emphasized. There is no difference in the clinical value of drugs, and the key is to meet the clinical needs of patients. The research and development of new Chinese medicines ignores the theoretical guidance of Chinese medicine, and relying solely on animal experiment data may lead to failure of clinical trials. Different from the individualized treatment of TCM clinical syndrome differentiation, summarizing the core pathogenesis of TCM is the basis for the development of new Chinese medicines. It is necessary to summarize the pathogenesis of the disease under the guidance of TCM theory and encourage the application of modern medical methods to clarify the diagnosis of the disease. In view of the characteristics of new Chinese medicine research and development, it is proposed that the supporting role of human experience should be emphasized, and the technical points of clinical trials of new syndrome-type Chinese medicines should be explained.The use of objective indicators for syndrome evaluation, the selection of appropriate scales, and the formulation of reasonable treatment courses are advocated. During the research and development of new Chinese medicines, it is not only necessary to pay attention to modern medical safety indicators, but also to observe the evolution of TCM syndromes and specific TCM symptoms.
